Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone41-61-565-6565
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.46 billion
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Actelion (OTCMKTS:ALIOF) Frequently Asked Questions
What is Actelion's stock symbol?
Actelion trades on the OTCMKTS under the ticker symbol "ALIOF."
How were Actelion's earnings last quarter?
Actelion Ltd (OTCMKTS:ALIOF) announced its quarterly earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing the Zacks' consensus estimate of $1.09 by $0.22. The business had revenue of $501.50 million for the quarter, compared to analyst estimates of $546.30 million. View Actelion's Earnings History.
Has Actelion been receiving favorable news coverage?
Headlines about ALIOF stock have trended positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Actelion earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Actelion's key competitors?
Some companies that are related to Actelion include Canopy Growth (CGC), Tilray (TLRY), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Rivers (RIV), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX) and GLG Life Tech (GLGLF).
Who are Actelion's key executives?
Actelion's management team includes the folowing people:
- Jean-Pierre Garnier Ph.D., Chairman of the Board of Directors (Age 69)
- Jean-Paul Clozel, Chief Executive Officer, Member of the Executive Committee, Delegate of the Board of Directors (Age 62)
- Thomas Widman, Co-Founder
- Andre C. Muller, Chief Financial Officer, Executive Vice President, Member of the Executive Committee (Age 53)
- Otto Schwarz, Chief Operating Officer, Executive Vice President, Member of the Executive Committee (Age 61)
- Guy Braunstein, Executive Vice President, Head of Global Clinical Development, Member of the Executive Committee (Age 60)
- Nicholas Franco, Executive Vice President, Chief Business Development Officer, Member of the Executive Committee (Age 54)
- Martine Clozel, Senior Vice President, Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Actelion Executive Committee (Age 61)
- Marian Borovsky, Senior Vice President, Group General Counsel, Member of the Extended Actelion Executive Committee, Corporate Secretary to the Board of Directors (Age 47)
- Christian Albrich, Senior Vice President, Head Global Human Resources, Member of the Extended Actelion Executive Committee (Age 52)
How do I buy shares of Actelion?
Shares of ALIOF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Actelion?
Actelion has a market capitalization of $0.00 and generates $2.46 billion in revenue each year.
What is Actelion's official website?
How can I contact Actelion?
Actelion's mailing address is Gewerbestrasse 16, Allschwil V8, 4123. The company can be reached via phone at 41-61-565-6565 or via email at [email protected]
MarketBeat Community Rating for Actelion (OTCMKTS ALIOF)
MarketBeat's community ratings are surveys of what our community members think about Actelion and other stocks. Vote "Outperform" if you believe ALIOF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIOF will underperform the S&P 500 over the long term. You may vote once every thirty days.
